This article is about ViiV's study of their long acting injected HIV medication, Cabenuva vs the daily Biktarvy. The injected med is a dual & the other is a daily, oral, triple ingredient medication. While I think this should've been done before going to market, at least it's being done now.
A point of concern is how much this research will include women in the study. The article uses the word, "women," multiple times. Most of the references are directly & actively referring to transgender women. Only the most indirect statement just used "women". HIV pharmaceutical research has been notably horrible about it's lack of inclusion of women in the studies.
We'll have to wait for the outcome.
Take care.
Cya...
No comments:
Post a Comment